advent
vaccin
repres
one
signific
advanc
medic
histori
protect
provid
vaccin
greatli
contribut
reduc
number
case
infect
notabl
erad
small
pox
larg
number
new
technolog
approach
vaccin
develop
current
investig
goal
provid
basi
next
gener
prophylact
everexpand
list
emerg
reemerg
pathogen
chapter
focu
role
lipid
lipid
selfassembl
vesicl
new
promis
vaccin
approach
start
describ
lipid
induc
activ
innat
immun
system
focu
increas
life
expect
last
centuri
arguabl
link
prevent
treatment
infect
regard
togeth
antibiot
vaccin
play
fundament
role
decreas
morbid
mortal
human
popul
last
decad
vaccin
contribut
abat
erad
mani
diseas
tabl
one
notabl
success
erad
small
pox
signific
reduct
case
poliomyel
global
case
per
year
late
case
tabl
moreov
immun
program
target
group
vaccineprevent
diseas
lowand
middleincom
countri
save
billion
direct
cost
probabl
indirect
cost
highlight
econom
contribut
public
health
initi
among
mani
result
exemplifi
past
success
contribut
vaccin
nonetheless
vaccin
also
revolution
futur
public
health
number
vaccin
ill
includ
cancer
age
group
benefit
expect
grow
tremend
proof
promis
futur
sever
initi
includ
bill
melinda
gate
foundat
stimul
research
applic
vaccin
better
captur
full
potenti
may
deliv
object
vaccin
establish
immunolog
memori
educ
adapt
immun
system
respond
infect
prevent
howev
new
approach
also
investig
possibl
use
vaccin
therapeut
certain
diseas
cancer
vaccin
compos
antigen
case
adjuv
antigen
compon
deriv
pathogen
diseas
prevent
treat
recogn
immun
system
product
specif
antibodi
adjuv
includ
need
increas
modul
product
antibodi
precis
accord
european
medicin
agenc
adjuv
compon
potenti
immun
respons
antigen
andor
modul
toward
desir
immun
respons
final
case
effect
deliveri
antigen
adjuv
requir
addit
vehicl
vector
worth
mention
effici
vaccin
estim
knowledg
accumul
studi
compon
antigen
vehicl
adjuv
separ
therefor
individu
character
everi
vaccin
formul
requir
toward
develop
new
better
vaccin
biomembran
lipid
play
fundament
role
excel
platform
deliveri
antigen
target
cell
proper
present
immun
system
vehiclevector
also
shown
excel
adjuv
howev
role
lipid
immun
respons
histor
ignor
best
releg
second
level
compar
import
given
protein
nucleic
acid
nonetheless
advanc
immunolog
vaccinolog
demonstr
lipid
potent
protein
nucleic
acid
mount
immun
respons
also
abil
modul
respons
trigger
antigen
modul
immun
system
driven
activ
stimul
cellular
receptor
innat
immun
system
passiv
influenc
stimuli
present
immun
cell
direct
activ
innat
immun
system
elicit
cellular
antivir
respons
also
particip
matur
traffick
dendrit
cell
dc
cell
crossprim
stimul
humor
immun
isotyp
switch
characterist
highli
desir
vaccin
adjuv
thu
interferon
ifn
cytokin
product
activ
innat
immun
system
ifninduc
molecul
includ
lipid
lipid
deriv
extens
explor
vaccin
adjuv
proof
potenc
lipid
stimul
immun
system
septic
shock
caus
hyperactiv
immun
system
bacteria
lipid
agonist
see
releas
bloodstream
chapter
explor
lipid
stimul
immun
system
knowledg
lead
new
line
vaccin
vaccin
adjuv
start
describ
innat
immun
respons
lipid
focus
activ
signal
cell
membranebound
receptor
immunostimulatori
lipid
next
introduc
role
lipid
lipid
deriv
vaccin
adjuv
final
explor
differ
type
lipidbas
vesicl
particularli
liposom
viruslik
particl
vlp
vaccin
vector
innat
cellular
immun
definit
cellular
respons
occur
immedi
infect
occur
innat
immun
contrast
adapt
immun
elicit
nonspecif
respons
pathogen
influenc
prior
contact
infecti
agent
primari
compon
broadspectrum
reactiv
system
identif
stimuli
trigger
respons
case
pathogen
invad
cell
identif
pathogen
reli
special
cellular
receptor
variabl
infecti
agent
potenti
infect
cell
enorm
furthermor
pathogen
mostli
due
genom
natur
rna
elev
replic
rate
fastevolv
organ
capabl
chang
lifetim
individu
thu
expand
variabl
stimuli
scenario
cell
encod
receptor
detect
pathogen
innat
immun
system
reli
identif
molecular
pattern
associ
infecti
agent
rather
identif
pathogen
individu
pattern
known
pathogenassoci
molecular
pattern
pamp
commonli
found
microb
absent
host
organ
consequ
recogn
foreign
entiti
cell
must
react
method
notselfrecognit
allow
identif
mani
pathogen
use
rel
small
repertoir
receptor
howev
specif
toward
individu
pathogen
poor
receptor
charg
fundament
task
call
pattern
recognit
receptor
prr
sever
class
prr
tolllik
receptor
tlr
ctype
lectin
receptor
ctlr
nodlik
receptor
nlr
rigilik
receptor
rlr
among
other
activ
one
depend
type
stimulu
also
locat
within
cell
instanc
extracellular
bacteria
activ
receptor
plasma
membran
intracellular
replic
virus
like
activ
solubl
receptor
cytosol
matter
fact
case
pathogen
activ
sever
prr
time
combin
inform
obtain
activ
multipl
prr
help
immun
system
compens
poor
specif
ppr
tailor
respons
type
pathogen
invad
cell
tabl
summar
local
human
tlr
famili
member
data
sourc
uniprot
stimuli
engag
receptor
subcellular
locat
quick
look
tlr
famili
human
reveal
breadth
stimuli
activ
innat
immun
system
also
import
lipid
lipid
deriv
immunostimul
precis
stimul
glycolipid
activ
upon
interact
lipoprotein
next
section
explor
peculiar
activ
signal
exampl
lipidactiv
prr
lipopolysaccharid
lp
princip
compon
cell
wall
gramneg
bacteria
escherichia
coli
approxim
lipid
residu
glycerophospholipid
singl
e
coli
cell
structur
lp
divid
three
part
fig
oantigen
oantigen
opolysaccharid
constitut
outermost
region
lp
largest
variabl
domain
compris
repetit
glycan
chain
oantigen
recogn
adapt
immun
system
antibodi
gener
howev
due
variabl
domain
antibodi
rais
oantigen
speci
specif
time
strain
specif
ii
core
oligosaccharid
core
oligosaccharid
link
oantigen
hydrophob
section
lp
lipid
constitut
two
part
outer
core
also
known
ocor
compos
hexos
residu
case
dglucos
dmannos
dgalactos
link
inner
core
constitut
oligosaccharid
usual
heptos
hep
acid
kdo
iii
lipid
lipid
lipidlik
domain
lp
actual
pamp
recogn
compos
two
phosphoryl
glucosamid
acyl
six
lipid
chain
variabl
length
fig
mention
tlr
engag
wide
varieti
stimuli
includ
lipid
lipoprotein
tabl
particularli
activ
bacteri
lp
fig
modular
structur
compos
extracellular
sens
domain
intracellular
signal
domain
connect
singl
transmembran
segment
anchor
protein
endosom
plasma
membran
fig
cytosol
side
respons
signal
cascad
initi
receptor
tir
domain
extracellular
domain
respons
sens
ligand
belong
leucinerich
repeat
lrr
famili
lrr
sequenc
repeat
present
varieti
protein
divers
function
involv
protein
interact
includ
proteinprotein
interact
proteinligand
interact
current
deep
knowledg
structur
detail
activ
fig
fact
sever
structur
complex
tir
domain
resolv
separ
eg
pdb
code
respect
furthermor
structur
transmembran
domain
recent
solv
nuclear
magnet
reson
pdb
code
complet
atomist
modular
descript
entir
receptor
recognit
process
lipid
start
lp
extract
bacteri
membran
two
accessori
protein
lpsbind
protein
next
actual
bind
lipid
occur
process
requir
adapt
protein
also
known
lymphocyt
antigen
fact
thought
protein
directli
recogn
bind
lipophil
part
lp
fold
structur
compos
two
antiparallel
sheet
form
hydrophob
pocket
lp
bound
mainli
hydrophob
interact
fig
bind
lp
drive
format
dimer
symmetr
complex
stoichiometri
liganddepend
dimer
initi
intracellular
signal
cascad
eventu
trigger
cellular
respons
bind
lp
disturb
structur
shape
receptor
retain
characterist
horsesho
shape
fig
interact
sustain
dimer
hydrophob
hydrophil
natur
one
hydrocarbon
chain
lipid
buri
hydrophob
pocket
acyl
chain
expos
left
interact
one
monom
furthermor
two
phosphat
group
lipid
interact
polar
residu
copi
hydrophob
hydrophil
interact
togeth
hydrogen
bond
ionic
interact
constitut
core
dimer
interfac
complet
descript
lipid
interact
visit
ref
bind
lipid
trigger
dimer
activ
signal
cascad
end
gener
appropri
cellular
respons
two
main
pathway
depend
select
use
differ
adaptor
combin
trigger
activ
pathway
fig
myeloid
differenti
primari
respons
protein
pathway
start
complex
locat
plasma
membran
cascad
begin
complex
intern
endosom
thu
membran
locat
adaptor
turn
defin
activ
pathway
local
signal
respons
add
new
level
complex
system
increas
specif
respons
facilit
mount
specif
respons
invad
pathogen
pathway
receptor
domaincontain
adapt
protein
tirap
adaptor
bind
dimer
tir
domain
fig
local
tirap
plasma
membran
mediat
phosphatidylinositol
domain
amino
terminu
protein
tir
domain
complex
recogn
subsequ
receptorassoci
kinas
fig
next
tnf
receptorassoci
factor
recruit
induc
activ
inhibitor
nuclear
factor
kappab
kinas
ikk
transform
growth
kinas
releas
activ
variou
mitogenactiv
protein
kinas
togeth
induc
product
proinflammatori
cytokin
fig
pathway
first
adaptor
molecul
signal
cascad
known
trifrel
adaptor
molecul
tram
tram
cotransl
modifi
addit
myristoyl
group
fatti
acyl
chain
facilit
local
otherwis
solubl
protein
endosom
membran
associ
stabil
electrostat
interact
phospholipid
tram
bound
capabl
recruit
trif
phosphoryl
cascad
activ
interferon
regulatori
factor
phosphoryl
dimer
transloc
nucleu
initi
transcript
type
interferon
fig
adjuv
latin
adjuvareto
help
definit
substanc
incorpor
vaccin
enhanc
immun
respons
toward
antigen
capabl
stimul
immun
system
trigger
product
cytokin
unabl
provid
longlast
protect
pathogen
adjuv
deliber
ad
vaccin
sinc
alum
aluminum
salt
accident
identifi
increas
antibodi
respons
vaccin
effici
sinc
much
discov
adjuv
activ
innat
immun
respons
nonimmun
immun
cell
adjuv
activ
dc
particularli
relev
lead
enhanc
antigen
uptak
migrat
lymph
node
prime
b
cell
thu
increas
vaccin
effici
interest
vaccin
adjuv
recent
increas
significantli
sever
reason
public
health
author
togeth
vaccin
manufactur
establish
ambiti
goal
enhanc
present
vaccin
definit
primari
function
adjuv
incorpor
adjuv
vaccin
prepar
enhanc
potenc
might
also
reduc
necessari
dose
increas
breadth
antibodi
respons
reduc
product
time
cost
addit
mani
new
vaccin
candid
current
investig
mani
case
new
vaccin
antigen
suffici
immunogen
could
benefit
supplement
adjuv
produc
efficaci
vaccin
despit
enorm
effort
adjuv
develop
hand
approv
adjuv
tabl
summar
approv
adjuv
unit
state
strikingli
approv
adjuv
either
agonist
oilinwat
emuls
word
lipidbas
adjuv
furthermor
mani
adjuv
investig
either
lipid
deriv
lipid
mimet
easili
engin
lipidbas
vaccin
next
section
focu
adjuv
exampl
lipidbas
adjuv
inher
toxic
lp
well
lipid
subunit
associ
high
potenc
stimul
immun
system
pose
safeti
risk
consid
use
vaccin
adjuv
howev
chemic
complex
lp
suggest
modif
might
made
order
detoxifi
compound
word
desir
adjuv
robustli
activ
innat
immun
system
drive
divers
cellular
humor
respons
given
pathogen
without
reactogen
caus
system
side
effect
mutant
strain
bacteria
defici
variou
step
lp
synthesi
isol
ultim
lp
assembl
pathway
raetz
pathway
defin
initi
e
coli
howev
similar
synthet
pathway
exist
gramneg
bacteria
bacteri
mutant
serv
import
reagent
enrich
variou
lipid
lp
precursor
later
scientist
began
work
mutant
bacteria
varieti
speci
includ
bordetella
pertussi
order
optim
immunogen
minim
reactogen
wholecel
vaccin
adjuv
endogen
lipid
deriv
chemic
modif
lp
extract
began
gener
new
speci
lipid
molecul
sinc
research
found
differ
lipid
variant
vari
degre
potenc
endotox
academ
lab
pharmaceut
compani
pursu
detoxifi
lipid
molecul
adjuv
viral
bacteri
vaccin
eventu
recogn
receptor
lp
lipid
deriv
differenti
signal
via
either
trif
adaptor
protein
gener
phenotyp
differ
respons
variou
ligand
speciesspecif
manner
addit
lp
deriv
small
molecul
agonist
develop
vaccin
adjuv
past
year
novel
purif
scheme
synthet
strategi
prolifer
search
lipid
aderiv
nonlipid
small
molecul
adjuv
usher
new
era
chemic
welldefin
subunit
vaccin
novel
adjuv
need
address
challeng
pathogen
hiv
pandem
influenza
virus
malaria
dengu
emerg
viral
pathogen
like
zika
viru
robust
humor
cellular
immun
requir
protect
host
monophosphoryl
lipid
mpla
heterogen
mixtur
chemic
modifi
lipid
molecul
deriv
lp
salmonella
minnesota
clinic
grade
mpla
term
mpl
adjuv
fda
approv
use
human
compon
adjuv
system
tabl
combin
mpl
alum
adjuv
cervarix
vaccin
human
papilloma
viru
strain
combat
cervic
cancer
cancer
also
licens
use
europ
compon
hepat
b
viru
vaccin
fendrix
mpl
adjuv
first
fda
approv
vaccin
adjuv
sinc
aluminum
salt
becom
part
vaccin
prepar
mpla
safe
efficaci
human
two
distinct
viral
vaccin
formul
heterogen
composit
suboptim
mpla
mixtur
tetra
penta
hexaacyl
lipid
molecul
singl
phosphoryl
group
polysaccharid
moieti
gener
chemic
enzymat
hydrolysi
purifi
lp
human
hexaacyl
lipid
deriv
tend
potent
agonist
tetraacyl
lipid
compon
mpla
shown
human
antagonist
activ
notabl
monophosph
lipid
retain
mpla
activ
howev
remov
phosphat
group
lipid
necessari
obtain
mpla
favor
safeti
profil
compar
lp
better
understand
signal
led
prolifer
ration
design
agonist
identifi
receptor
lp
subsequ
demonstr
could
signal
trif
discuss
elsewher
greater
detail
see
fig
schemat
represent
signal
pathway
recognit
mpla
signal
primarili
trif
adaptor
protein
spur
develop
trifselect
ligand
vaccin
adjuv
parallel
activ
stimul
transcript
factor
mitogenactiv
protein
kinas
induc
primarili
inflammatori
cytokin
activ
trif
lead
downstream
activ
via
uniqu
intracellular
signal
rel
induc
type
interferon
addit
inflammatori
cytokin
therefor
endotox
lp
depend
upon
proinflammatori
cytokin
activ
via
mice
defici
resist
lpsinduc
septic
shock
contrast
induct
type
interferon
trif
signal
respons
favor
adjuv
qualiti
lipid
includ
induct
immun
respons
observ
mpla
understand
sever
complex
ligand
ration
design
viral
bacteri
vaccin
adjuv
noteworthi
preclin
clinic
synthet
lipid
analog
includ
glucopyranosyl
lipid
adjuv
gla
aminoalkyl
glucosaminid
agp
disaccharid
backbon
structureact
relationship
studi
agp
demonstr
rel
small
stereochem
chang
lipid
structur
affect
charg
group
hydrophil
portion
lipid
interact
may
substanti
affect
downstream
trif
signal
minim
affect
abil
medicin
chemist
modul
trif
signal
tremend
opportun
optim
adjuv
gla
advanc
clinic
trial
demonstr
safeti
immunogen
fulli
synthet
lipid
analog
human
given
regulatori
safeti
concern
wholli
synthet
molecul
welldefin
mechan
action
may
repres
futur
adjuv
come
clinic
use
lipid
deriv
name
mpla
alreadi
enjoy
clinic
success
vaccin
adjuv
complex
molecul
make
purif
chemic
modif
vaccin
formul
challeng
like
result
complex
interact
lp
signal
apparatu
rel
famili
small
molecul
agonist
report
date
highthroughput
screen
success
produc
candid
vaccin
adjuv
includ
distinct
nonlipid
chemic
entiti
substitut
pyramid
indol
deriv
amid
synthes
via
ugi
reaction
small
molecul
ligand
demonstr
preclin
potenti
vaccin
adjuv
potent
immunostimulatori
potenti
limit
reactogen
mous
small
molecul
advantag
purifi
lp
deriv
mpla
singl
defin
chemic
speci
howev
research
small
molecul
agonist
infanc
yet
unclear
whether
compound
clinic
impact
structur
complex
lipid
provid
scientist
ampl
opportun
genet
chemic
modif
optim
adjuv
toxic
interact
agonist
signal
apparatu
straightforward
present
uniqu
challeng
opportun
preclin
anim
model
vitro
cultur
system
play
essenti
role
evalu
potenc
cytokin
profil
particular
adjuv
anim
model
need
evalu
preclin
safeti
efficaci
intact
immun
system
necessari
fulli
evalu
protect
efficaci
adjuv
vaccin
express
ligand
variabl
differ
tissu
anim
ligand
exhibit
speciesspecif
phenotyp
variabl
regard
adjuv
toxic
profil
fact
lipid
precursor
tetraacyl
lipid
iva
shown
agonist
murin
cell
antagon
human
potent
human
agonist
name
ugi
compound
describ
littl
activ
rang
preclin
model
includ
mous
rat
rabbit
ferret
cotton
rat
cell
speciesspecif
structur
differ
human
mous
complex
identifi
affect
receptor
interact
given
ligand
lipid
iva
bind
murin
receptor
similar
pattern
lp
howev
lipid
iva
antagonist
human
crystal
human
bound
differ
conform
pattern
compar
lp
number
strategi
develop
order
circumv
problem
simpli
one
may
screen
molecul
activ
human
murin
cell
chemic
genet
enzymat
modif
candid
compound
lipid
prepar
may
employ
develop
adjuv
candid
signal
promiscu
new
anim
model
develop
close
resembl
human
signal
includ
transgen
mous
model
express
human
mice
defici
murin
effect
reconstitut
lp
signal
comput
model
defin
structur
chemic
determin
ligandreceptor
interact
may
also
help
overcom
speci
barrier
drive
ration
design
agonist
activ
across
rang
speci
last
year
seen
larg
increas
potenti
applic
nanoparticl
medic
purpos
fact
thought
applic
nanotechnolog
revolution
drug
deliveri
methodolog
distant
futur
vaccinolog
except
nanoparticl
expect
enorm
impact
futur
vaccin
develop
among
differ
type
nanoparticl
includ
inorgan
nanoparticl
polymer
nanoparticl
carbon
nanotub
nanogel
lipidbas
nanoparticl
lbn
extens
use
prefer
lipidderiv
vesicl
respond
high
deliveri
effici
also
capac
deliv
larg
varieti
cargo
adapt
requir
specif
treatment
next
section
focu
liposom
sinc
best
known
use
selfassembl
lbn
nonetheless
multipl
variat
classic
liposom
nonliposom
lbn
investig
preclin
earlier
phase
develop
process
bestknown
lbn
summar
tabl
excel
updat
review
properti
applic
formul
advanc
technolog
see
ref
liposom
first
util
medic
purpos
rapidli
potenti
vaccin
deliveri
vehicl
explor
togeth
adjuv
properti
current
novemb
clinic
trial
regist
http
clinicaltrialsgov
open
servic
us
nation
institut
health
http
clinicaltrialsgov
search
term
liposom
vaccin
tabl
thu
demonstr
enorm
potenti
type
formul
futur
vaccin
develop
liposom
compos
predominantli
phospholipid
abund
lipid
biolog
membran
phospholipid
amphiphil
lipid
molecul
contain
polar
head
group
made
phosphat
bound
addit
group
variabl
natur
head
lipid
link
glycerol
group
hydrophob
tail
constitut
two
fatti
acid
chain
amphiphil
structur
facilit
selfassembl
aqueou
environ
result
vesicl
hydrophob
hydrophil
region
ideal
incorpor
differ
type
antigen
watersolubl
protein
would
includ
liposom
core
bound
polar
surfac
vesicl
hydrophob
antigen
would
insert
liposom
membran
one
main
advantag
liposom
physicochem
properti
tune
meet
requir
antigen
characterist
head
group
crucial
determin
surfac
properti
vesicl
fluiditi
permeabl
stabil
depend
length
degre
satur
acyl
chain
characterist
tremend
impact
deliveri
antigen
eg
liposom
contain
phosphatidylserin
enhanc
phagocytosi
macrophag
type
immun
respons
trigger
vaccin
eg
immun
small
liposom
induc
respons
larg
liposom
trigger
respons
vast
amount
literatur
liposomalbas
vaccin
refer
use
chapter
meant
introduc
reader
field
serv
comprehens
list
physiochem
properti
liposom
vaccin
recent
review
bernasconi
et
al
liposom
vaccin
formul
summar
charlton
hume
lua
mani
type
antigen
success
incorpor
liposom
peptid
protein
common
antigen
use
vaccin
prepar
peptid
liposom
shown
efficaci
mani
time
multipl
applic
includ
protect
larg
varieti
pathogen
cancer
furthermor
peptid
deliv
via
liposom
formul
extens
use
mani
immunolog
studi
stimul
humor
respons
eg
taenechi
colleg
recent
demonstr
liposomecoupl
peptid
induc
longliv
memori
cell
without
cell
use
liposomebas
vaccin
protein
fulllength
partial
sequenc
also
success
incorpor
liposom
vaccin
fact
earli
work
liposom
vaccin
protein
alreadi
use
immunogen
nonetheless
use
protein
liposomebas
vaccin
still
investig
new
applic
formul
current
investig
eg
recent
work
mimet
envelop
protein
hiv
use
accomplish
viru
neutral
use
highdens
liposom
formul
vaccin
use
nucleic
acid
reli
cellular
transcript
translat
machineri
produc
antigen
deliveri
antigen
via
dnarna
vaccin
promis
altern
proteinbas
vaccin
especi
difficult
produc
recombin
form
addit
current
nucleic
acid
synthesi
technolog
allow
tailor
rapid
inexpens
product
new
antigen
characterist
would
make
dnarna
vaccin
ideal
chang
scenario
emerg
new
pandem
eg
recent
ebola
pandem
constant
reemerg
continu
evolv
pathogen
howev
immunogen
nake
nucleic
acid
vaccin
weak
case
insuffici
success
vaccin
due
degrad
andor
ineffici
target
immun
cell
dnarna
furthermor
deliveri
genet
materi
cell
overcom
mani
obstacl
eg
endosom
escap
lysosom
degrad
nuclear
uptak
mani
hurdl
could
overcom
use
adequ
vector
make
nucleic
acid
vaccin
viabl
altern
liposom
shown
effici
deliv
nucleic
acid
vitro
use
promptli
vivo
vaccin
nonetheless
first
formul
liposom
vaccin
although
capabl
enhanc
effici
nucleic
acid
vaccin
complet
overcom
mani
previous
mention
obstacl
associ
dnarna
vaccin
howev
advanc
liposom
formul
mitig
limit
reduc
offtarget
effect
new
technolog
revolution
dnarna
vaccin
field
could
becom
viabl
option
soon
liposomebas
dnarna
vaccin
proven
especi
success
case
oral
vaccin
nucleic
acidbas
oral
vaccin
repres
ideal
combin
antigen
deliveri
rout
top
potenti
benefit
dnarna
vaccin
oral
administr
might
elimin
mani
prejudic
associ
vaccin
could
facilit
massiv
vaccin
campaign
even
third
world
countri
consequ
nucleic
acid
antigen
liposom
vehicl
oral
administr
current
gather
lot
attent
human
also
anim
vaccin
enorm
versatil
physic
paramet
lipid
constitut
liposom
util
construct
tailormad
vehicl
wide
rang
applic
liposom
act
vaccin
deliveri
system
also
function
vaccin
adjuv
liposom
even
constitut
mainli
phospholipid
adjuv
activ
two
main
reason
adjuv
liposom
enhanc
antigen
uptak
antigenpres
cell
includ
cd
liposom
like
oilinwat
emuls
depot
effect
depot
effect
oldest
adjuv
mechan
describ
antigen
entrap
site
inject
slow
releas
antigen
facilit
continu
stimul
antigenpres
cell
correl
high
antibodi
titer
advanc
liposom
base
adjuv
properti
multipl
mechan
besid
depot
effect
modif
physicochem
characterist
liposom
modifi
type
immun
respons
modul
exposur
recruit
immun
cell
eg
li
colleagu
show
small
liposom
nm
induc
stronger
respons
ova
peptid
larger
vesicl
nm
later
use
leishmaniasi
antigen
shown
small
liposom
stimul
respons
larg
one
induc
respons
accompani
higher
interferon
gamma
level
furthermor
head
group
charg
thoroughli
investig
shown
liposom
differ
net
charg
differ
adjuv
activ
nonetheless
outcom
respons
also
influenc
antigen
thu
difficult
predict
properti
liposom
import
locationinteract
antigen
liposom
also
modul
immun
respons
barnierqu
et
al
show
influenza
hemagglutinin
adsorb
surfac
liposom
immunogen
encapsul
inclus
addit
adjuv
agent
enhanc
modul
vaccin
immunoproperti
liposom
formul
incorpor
lipid
lipidlik
adjuv
agonist
discuss
previous
beyond
commonli
use
adjuv
liposomebas
vaccin
cpg
short
singlestrand
dna
molecul
contain
cytosin
triphosph
deoxynucleotid
guanin
triphosph
deoxynucleotid
dna
motif
often
found
bacteri
dna
recogn
pamp
cpg
thought
activ
dc
matur
increas
antigen
express
induc
immun
respons
poli
c
polyinosin
polycytidyl
acid
synthet
mimet
doublestrand
rna
capabl
stimul
immun
system
tlr
rlr
famili
poli
c
strongli
drive
cellmedi
immun
potent
type
interferon
respons
consist
synthet
glycolipid
tdb
incorpor
cation
dda
dimethyldioctadecylammonium
bromid
liposom
lead
high
level
secret
low
level
secret
tcell
induc
strong
immun
respons
mdp
muramyl
dipeptid
mdp
synthet
immunoreact
peptid
consist
nacetyl
muram
acid
attach
lalanin
disoglutamin
dipeptid
mdp
constitu
gramposit
gramneg
bacteria
recogn
prr
pamp
activ
product
inflammatori
cytokin
fatti
acyl
analog
mdp
also
investig
adjuv
liposom
prepar
breadth
molecul
incorpor
liposom
enhanc
vaccin
efficaci
increas
rapidli
includ
deoacyl
lipooligosaccharid
novel
agonist
capabl
enhanc
humor
cellular
immun
respons
variat
formul
previous
describ
immun
receptor
fc
receptor
peptid
receptor
igg
fc
fragment
enhanc
uptak
antigen
dc
vlp
noninfecti
viral
particl
resembl
wildtyp
virion
structur
lack
viral
genomerend
unabl
replic
vlp
typic
gener
viralencod
capsid
andor
envelop
protein
drive
bud
virion
case
envelop
virus
vlp
repres
lipid
membran
deriv
host
cell
thu
similar
lipid
composit
membran
consid
viral
membran
may
also
incorpor
viral
encod
surfac
protein
given
intrins
natur
selfassembl
particl
rel
eas
product
vlp
greatli
contribut
last
three
decad
numer
field
studi
vaccinolog
virushost
interactionsviru
replic
cycl
structur
biolog
gene
therapi
bionanotechnolog
even
case
highli
pathogen
virus
see
particularli
vaccinolog
vlp
repres
one
util
tool
due
favor
immunolog
characterist
notabl
candid
vlpbase
vaccin
highli
pathogen
virus
extens
pursu
due
abil
present
chief
target
immun
system
noninfecti
platform
moreov
eas
vlp
manufactur
larg
batch
sever
type
host
express
system
eg
insect
bacteria
make
vlpbase
vaccin
good
altern
safe
fast
method
develop
prophylact
urgent
situat
current
sever
vlpbase
vaccin
commerci
avail
includ
cervarix
thirdgener
hepat
b
viru
scibvac
vaccin
mani
current
investig
follow
text
mainli
focu
vlp
deriv
famili
virus
infect
mammal
howev
note
vlp
deriv
mammalian
virus
still
produc
heterolog
host
system
first
exampl
recombin
vlp
gener
vitro
express
coat
protein
hepat
b
viru
hbv
core
antigen
hbcag
hbv
surfac
antigen
hbsag
tobacco
mosaic
viru
analysi
hbcag
vlp
via
electron
microscopi
subsequ
show
vlp
ident
core
shell
harvest
hbvinfect
liver
cell
demonstr
first
time
recombin
vlp
resembl
nativ
viral
particl
isol
infect
cell
advent
new
gener
vaccin
hbv
human
papilloma
viru
base
vlp
increas
interest
gener
novel
strategi
vlpbase
vaccin
nanoparticl
deliveri
system
thu
surpris
medicalbas
applic
vlp
develop
vaccin
infecti
diseas
larg
number
vlp
form
highli
order
symmetr
complex
deriv
structur
capsid
protein
nonenvelop
virus
list
icosahedr
vlp
differ
virus
briefli
describ
tabl
vlp
gener
hbv
surfac
antigen
one
bestcharacter
particl
basi
success
hbv
vaccin
sinc
structur
recapitul
nativ
subvir
particl
releas
bloodstream
hbvinfect
individu
higher
infecti
complet
virion
particlesml
specul
major
role
subvir
particl
sequesterinduc
neutral
antibodi
complet
virion
act
immun
evas
techniqu
viral
infect
exact
mechan
hbsag
lipoprotein
selfassembl
yet
fulli
elucid
evid
vlp
studi
intraand
intermolecular
disulfid
bond
requir
proper
recapitul
antigen
immunogen
properti
subvir
particl
interest
note
subvir
particl
use
develop
first
gener
hbv
vaccin
great
success
sphericalshap
vlp
also
gener
sever
famili
virus
tabl
vlp
gener
gag
protein
retrovirus
also
pursu
mani
research
group
express
gag
suffici
form
retroviru
vlp
although
multipl
strategi
combin
viral
protein
gener
vlpswith
stipul
viral
replic
andor
integr
initi
may
involv
genet
remov
viral
enzym
revers
transcriptas
integras
convers
retrovir
vlp
compos
multipl
immunolog
target
stimul
humor
antibodi
cellular
respons
without
deleteri
effect
liveattenu
vaccin
inde
vlp
express
nativ
form
envelop
protein
elicit
strong
humor
cellular
respons
lead
antibodydepend
cellmedi
immun
third
group
virus
use
gener
helic
filament
type
vlp
summar
tabl
notabl
influenza
virus
orthomyxovirida
famili
virus
produc
spheric
helic
vlp
depend
experiment
condit
howev
must
also
emphas
clinic
isol
influenza
virus
produc
pleomorph
viral
particl
includ
long
filament
virion
nonetheless
product
influenza
viruslik
particl
requir
hemagglutinin
neuraminidas
matrix
protein
one
effici
egress
transient
express
two
surfac
glycoprotein
hemagglutinin
neuraminidas
suffici
bud
product
vlp
howev
inclus
matrix
protein
hemagglutinin
neuraminidas
gener
filament
vlp
similar
natur
clinic
isol
viral
particl
numer
approach
gener
plethora
influenza
viruslik
particl
wide
rang
influenza
viral
subtypesspecif
zoonot
virus
caus
yearli
sporad
outbreak
howev
lot
work
remain
done
address
breadth
efficaci
longev
respons
elicit
note
prototyp
virusu
produc
filament
matur
vlp
member
filovirida
orthomyxovirida
negativesens
rna
influenza
viru
follow
section
role
vlp
filoviru
research
specif
ebola
viru
ebov
discuss
vlp
vaccin
also
benefit
incorpor
adjuv
like
liposomalbas
vaccin
vlp
immunogen
boost
use
wide
rang
adjuv
includ
prr
lipid
analog
poli
c
cpg
iscomatrix
complex
adjuv
compos
saponin
glycosid
extract
quillaja
saponaria
cholesterol
phospholipid
complet
review
adjuv
formul
vlpbase
vaccin
visit
ref
ebov
prototyp
viral
speci
filovirida
famili
pathogen
caus
deadli
sporad
outbreak
hemorrhag
fever
diseas
known
ebola
viru
diseas
gener
character
malais
headach
fever
hypotens
myalgia
edema
vascular
permeabl
blood
coagul
dysregul
hemorrhag
administr
antibodybas
therapi
shown
promis
recent
outbreak
ebov
west
africa
current
fdaapprov
vaccin
ebov
toward
better
understand
clinic
hallmark
ebov
infect
much
work
still
need
elucid
molecular
determin
ebov
pathogenesi
defin
optim
immun
respons
protect
one
major
obstacl
ebov
research
requir
perform
experi
highest
biosafeti
level
condit
significantli
curtail
slow
scientif
progress
experiment
use
ebov
vlp
howev
greatli
contribut
elucid
viral
replic
identifi
molecular
determin
pathogenesi
ebov
negativesens
nonseg
rna
viru
encod
seven
structur
protein
one
nonstructur
protein
viral
rna
genom
encapsid
nucleoprotein
np
associ
viral
l
polymeras
alongsid
noncatalyt
cofactor
transcript
activ
complex
call
ribonucleoprotein
rnp
matur
infecti
ebov
particl
compos
viral
rnp
surround
hostderiv
plasma
membran
envelop
stud
viral
encod
glycoprotein
gp
two
matrix
protein
bridg
gap
rnp
associ
intern
region
viral
envelop
find
transient
express
ebov
sole
suffici
viru
bud
conserv
prolinerich
motif
py
nterminu
cterminu
region
gener
filoviruslik
particl
signific
contribut
field
subsequ
studi
demonstr
coexpress
gp
produc
filament
virionlik
particl
express
gp
surfac
earli
observ
gener
noninfecti
ebov
vlp
greatli
contribut
describ
step
viral
replic
cycl
bypass
work
perform
condit
one
exampl
work
perform
martinez
colleagu
reveal
import
hostand
tissuespecif
restrict
ebov
infect
diseas
util
vlp
entri
assay
wildtyp
ebov
infect
nonhuman
primat
highli
lethal
experiment
infect
mice
guinea
pig
lethal
anim
succumb
diseas
toward
elucid
determin
ebov
hostand
tissuespecif
tropism
research
focus
gp
mediat
viral
attach
entri
permiss
cell
studi
role
gp
tropism
cell
transient
transfect
plasmid
encod
ebov
fuse
anoth
plasmid
encod
ebov
gpresult
ebov
vlp
express
report
gene
success
entri
vlp
detect
measur
enzym
activ
addit
substrat
previous
shown
mutat
site
gp
phenylalanin
alanin
decreas
affin
gp
human
niemannpick
protein
essenti
filoviru
receptor
higher
express
rescu
vlp
mutat
closer
look
differenti
express
murin
cell
reveal
pattern
cell
higher
express
permiss
intern
vlp
express
mutant
version
cell
find
provid
evid
region
within
gp
influenc
affin
host
cell
receptor
affect
host
cell
rang
ebov
abil
produc
ebov
vlp
also
provid
method
investig
virushost
interact
govern
bud
phase
filovirus
similar
method
describ
earlier
util
gener
vlp
express
report
gene
gener
understood
selfassembl
oligomer
viral
protein
ebov
major
drive
forc
bud
matur
virion
later
stage
viral
replic
virushost
interact
play
crucial
role
facilit
effici
viral
egress
recent
studi
investig
show
interact
host
suppressor
cytokin
signal
enhanc
ubiquitinyl
egress
inde
overexpress
correl
increas
bud
ebov
vlp
previou
studi
overexpress
host
ubiquitin
ligas
interact
ppxi
domain
enhanc
ebov
vlp
bud
